The results of the study demonstrated a significant improvement in progression-free survival (PFS) when patients with EGFR-mutated advanced NSCLC were treated with an EGFR tyrosine kinase inhibitor (TKI) monotherapy compared to standard chemotherapy (Pezzuto et al. 2017). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.